Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MMP1 | P03956 | 2/20 | 0.37 |
| ▸ | MMP2 | P08253 | 2/20 | 0.37 |
| ▸ | MMP9 | P14780 | 2/20 | 0.37 |
| ▸ | MMP12 | P39900 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6922997 | 0.84 | L3MBTL1 (0.38) | KMT2AMAOBRIPK1 | |
| SCHEMBL6750713 | 0.69 | KDM4E (0.46) | MMP1MMP2MMP9MMP12MAPT | |
| SCHEMBL6747019 | 0.67 | MAPT (0.37) | RECQLKMT2AMAPTP2RY12HTR7 | |
| SCHEMBL6750632 | 0.63 | HTR7 (0.39) | KMT2AHTR7 | |
| SCHEMBL6750671 | 0.63 | THRB (0.45) | KMT2AMMP1MMP2MMP9MMP12 | |
| SCHEMBL5335214 | 0.62 | MAPT (0.63) | KMT2AMMP1MMP2MMP9MMP12 | |
| SCHEMBL2573338 | 0.60 | TDP1 (0.69) | KMT2AMMP1MMP2MMP9MMP12 | |
| SCHEMBL31539395 | 0.60 | TDP1 (0.69) | KMT2AMMP1MMP2MMP9MMP12 | |
| SCHEMBL28220772 | 0.60 | KMT2A (0.69) | KMT2AMMP1MMP2MMP9MMP12 | |
| SCHEMBL18827686 | 0.60 | TDP1 (0.58) | KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040043984-A1 | 3,4-Dihydroquinolin-2-one, 5,6-fused oxazin-3-one, and 5,6-fused thiazin-3-one derivatives as matrix metalloproteinase inhibitors | O'BRIEN PATRICK MICHAEL (US) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043984-A1 | 3,4-Dihydroquinolin-2-one, 5,6-fused oxazin-3-one, and 5,6-fused thiazin-3-one derivatives as matrix metalloproteinase inhibitors | MMP13, MMP9, MMP3 | PTK2 922/4885RECQL 941/4885KMT2A 2652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.